AKT is overexpressed in 50–70% of NSCLC tumors[6] and accordingly, AKT inhibitors MK-2206 and AZD5363 are currently undergoing clinical trials for lung cancer treatment. This evidence concerns the gene AKT1 and lung carcinoma.